KR920700678A - 항-박테리아 성분물 - Google Patents
항-박테리아 성분물Info
- Publication number
- KR920700678A KR920700678A KR1019910700615A KR910700615A KR920700678A KR 920700678 A KR920700678 A KR 920700678A KR 1019910700615 A KR1019910700615 A KR 1019910700615A KR 910700615 A KR910700615 A KR 910700615A KR 920700678 A KR920700678 A KR 920700678A
- Authority
- KR
- South Korea
- Prior art keywords
- milk
- pneumoniae
- influenza
- extracted
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
- A23J1/202—Casein or caseinates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Housing For Livestock And Birds (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 소초유가 H.인플루엔자와 S.뉴모니아에 의한 흡착을 저해하는 것을 나타낸 것이다. 제2도는 카제인 농도와 흡착 저해도 사이의 상관관계를 나타낸 것이다. 제3도는 카파-카제인 농도와 흡착도 사이의 상관관계를 나타낸 것이다.
Claims (7)
- S.뉴모니아와 H.인플루엔자에 의한 호흡기 감염의 치료, 예방과 진단에 이용되는 제약학적인 성분물을 제조하는데 있어서 우유에서 추출한 분자량이 5000 달톤이상인 저분자로 구성된 카제인 프렉션(fraction)의 용도.
- 제1항에 있어서, 카제인은 인유, 소젖과 돼지젖에서 추출한 것으로 분자량이 5000달톤이상인 것을 특징으로 하는 용도.
- S.뉴모니아와 H.인플루엔자에 의한 호흡기 감염의 치료, 예방과 진단에 이용되는 것으로 우유에서 추출한 분자량이 5000달톤 이상인 저분자로된 카제인 플랙션의 효과량으로 구성된 것을 특징으로 하는 제약학적 성분물.
- 제3항에 있어서, S. 뉴모니아에 의한 감염의 치료, 또는 예방을 위한 인유, 소젖, 돼지젖에서 추출한 카제인의 치료효과와 살균효과량으로 구성된 것을 특징으로 하는 제약학적 성분물.
- S.뉴모니아 또는 H.인플루엔자에 의한 호흡기 감염의 치료, 또는 예방을 위한 우유에서 추출한 5000 달톤이상의 저분자로된 카제인 플렉션이 활성양이 첨가된 것을 특징으로 하는 음식과 사료.
- S.뉴모니아또는 H.인플루엔자에 의한 감염의 치료 또는 예방에 있어서, 우유에서 추출한 분자량이 5000달톤이상인 카제인의 효과량과 제약학적으로 비활성 촉진제 또는 영양제와 복합하여 포유류(사람 포함)에 주입시키는 것으로 구성된 것을 특징으로 하는 치료 및 예방방법.
- S.뉴모니아또는 H.인플루엔자에 의해 감염된 포유류(사람포함)에서 추출한 샘플조직에 제1항 내지 2항에 따르는 성분물의 흡착도를 검사함으로써 S.뉴모니아또는 H.인플루엔자에 의한 감염을 진단하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE8903625-5 | 1989-10-30 | ||
SE8903625A SE465109B (sv) | 1989-10-30 | 1989-10-30 | Antibakteriell komposition |
PCT/SE1990/000702 WO1991006308A1 (en) | 1989-10-30 | 1990-10-30 | A casein fraction for therapeutic, profylactic and/or diagnostic use in infections of the respiratory tract |
Publications (1)
Publication Number | Publication Date |
---|---|
KR920700678A true KR920700678A (ko) | 1992-08-10 |
Family
ID=20377332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019910700615A KR920700678A (ko) | 1989-10-30 | 1990-10-30 | 항-박테리아 성분물 |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0454813B1 (ko) |
JP (1) | JPH04503077A (ko) |
KR (1) | KR920700678A (ko) |
AT (1) | ATE170754T1 (ko) |
AU (1) | AU633647B2 (ko) |
CA (1) | CA2044244A1 (ko) |
DE (1) | DE69032646T2 (ko) |
DK (1) | DK0454813T3 (ko) |
ES (1) | ES2121755T3 (ko) |
FI (1) | FI102516B (ko) |
HU (1) | HU212935B (ko) |
NO (1) | NO912391D0 (ko) |
RU (1) | RU2035913C1 (ko) |
SE (1) | SE465109B (ko) |
WO (1) | WO1991006308A1 (ko) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506209A (en) * | 1994-05-26 | 1996-04-09 | Abbott Laboratories | Product for inhibition of infection of mammalian cells by respiratory syncytial virus |
JPH10500101A (ja) * | 1994-05-26 | 1998-01-06 | アボツト・ラボラトリーズ | インフルエンザ菌のヒト細胞への付着の阻害 |
US5707968A (en) * | 1994-05-26 | 1998-01-13 | Abbott Laboratories | Inhibition of attachment of H.influenzae to human cells |
JPH10500100A (ja) * | 1994-05-26 | 1998-01-06 | アボツト・ラボラトリーズ | 哺乳動物細胞のrsウイルス感染の阻害 |
US5538952A (en) * | 1994-05-26 | 1996-07-23 | Abbott Laboratories | Inhibition of infection of mammalian cells by respiratory syncytial virus |
US5643880A (en) * | 1994-05-26 | 1997-07-01 | Abbott Laboratories | Product for inhibition of attachment of H. influenzae to human cells |
US5942254A (en) * | 1995-02-27 | 1999-08-24 | Abbott Laboratories | Phosphorylated recombinant human β-casein expressed in a bacterial system |
ATE246934T1 (de) * | 1995-11-06 | 2003-08-15 | Abbott Lab | Phosphoryliertes rekombinantes menschliches beta- kasein für die hemmung der anheftung von h. influenzae an menschlichen zellen |
JP2000500141A (ja) * | 1995-11-06 | 2000-01-11 | アボツト・ラボラトリーズ | リン酸化された組換えヒトベータ−カゼインを用いるヒト細胞に対するインフルエンザ菌の付着阻止方法 |
AUPP494798A0 (en) | 1998-07-29 | 1998-08-20 | Pacific Biolink Pty Limited | Protective protein formulation |
CA2507018C (en) | 2002-11-26 | 2014-03-25 | John C. Alverdy | Materials and methods for preventing and treating microbe-mediated epithelial disorders |
AU2008275542B2 (en) * | 2007-07-06 | 2014-06-05 | Laclede, Inc. | Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1496671A (en) * | 1975-03-27 | 1977-12-30 | Grindstedvaerket As | Anti-cancer-active sour milk fraction |
FR2491334A1 (fr) * | 1980-10-03 | 1982-04-09 | Inst Nat Sante Rech Med | Nouvelles substances biologiquement actives, leur obtention a partir de caseine humaine et compositions les contenant |
FR2592769B1 (fr) * | 1986-01-10 | 1990-10-12 | Agronomique Inst Nat Rech | Procede d'obtention d'une matiere enrichie en caseine beta, appareillage pour la mise en oeuvre de ce procede, et application des produits obtenus par ce procede comme aliments, complements alimentaires ou additifs en industrie alimentaire et pharmaceutique ou dans la preparation de peptides a activite physiologique |
JP2631470B2 (ja) * | 1987-05-15 | 1997-07-16 | 雪印乳業株式会社 | 感染防御剤 |
-
1989
- 1989-10-30 SE SE8903625A patent/SE465109B/sv not_active IP Right Cessation
-
1990
- 1990-10-30 HU HU912203A patent/HU212935B/hu not_active IP Right Cessation
- 1990-10-30 AU AU66470/90A patent/AU633647B2/en not_active Ceased
- 1990-10-30 KR KR1019910700615A patent/KR920700678A/ko not_active Application Discontinuation
- 1990-10-30 DK DK90916537T patent/DK0454813T3/da active
- 1990-10-30 CA CA002044244A patent/CA2044244A1/en not_active Abandoned
- 1990-10-30 ES ES90916537T patent/ES2121755T3/es not_active Expired - Lifetime
- 1990-10-30 EP EP90916537A patent/EP0454813B1/en not_active Expired - Lifetime
- 1990-10-30 WO PCT/SE1990/000702 patent/WO1991006308A1/en active IP Right Grant
- 1990-10-30 JP JP2515465A patent/JPH04503077A/ja active Pending
- 1990-10-30 AT AT90916537T patent/ATE170754T1/de not_active IP Right Cessation
- 1990-10-30 DE DE69032646T patent/DE69032646T2/de not_active Expired - Fee Related
-
1991
- 1991-06-19 NO NO912391A patent/NO912391D0/no unknown
- 1991-06-28 RU SU914895868A patent/RU2035913C1/ru active
- 1991-06-28 FI FI913154A patent/FI102516B/fi active
Also Published As
Publication number | Publication date |
---|---|
DE69032646T2 (de) | 1999-05-27 |
SE465109B (sv) | 1991-07-29 |
EP0454813A1 (en) | 1991-11-06 |
FI913154A0 (fi) | 1991-06-28 |
ATE170754T1 (de) | 1998-09-15 |
FI102516B1 (fi) | 1998-12-31 |
AU6647090A (en) | 1991-05-31 |
CA2044244A1 (en) | 1991-05-01 |
FI102516B (fi) | 1998-12-31 |
EP0454813B1 (en) | 1998-09-09 |
JPH04503077A (ja) | 1992-06-04 |
WO1991006308A1 (en) | 1991-05-16 |
ES2121755T3 (es) | 1998-12-16 |
SE8903625D0 (sv) | 1989-10-30 |
NO912391L (no) | 1991-06-19 |
RU2035913C1 (ru) | 1995-05-27 |
DE69032646D1 (de) | 1998-10-15 |
NO912391D0 (no) | 1991-06-19 |
HU212935B (en) | 1996-12-30 |
SE8903625L (sv) | 1991-05-01 |
AU633647B2 (en) | 1993-02-04 |
DK0454813T3 (da) | 1999-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fair et al. | Prostatic antibacterial factor identity and significance | |
KR920700678A (ko) | 항-박테리아 성분물 | |
Reimers et al. | Borrelia burgdorferi myositis: report of eight patients | |
DE69636228D1 (de) | Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen | |
Blaser | Editorial Response: Campylobacter fetus: Emerging Infection and Model System for Bacterial Pathogenesis at Mucosal Surfaces | |
US4844894A (en) | Method of inhibiting the onset of septicemia and endotoxemia | |
BR9814615A (pt) | Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa | |
Cole et al. | Interactions of mycoplasmas and their products with lymphoid cells in vitro | |
Lauschke et al. | Hematogenous osteomyelitis in infants and children in the northwestern region of Namibia. Management and two-year results. | |
JP2001072582A (ja) | 機能性経口組成物 | |
Ljungh et al. | Aeromonas hydrophila toxins—intestinal fluid accumulation and mucosal injury in animal models | |
OCHIAI et al. | Neuroimaging of a Wooden Foreign Body Retained for 5 Months in the Temporalis Muscle Following Penetrating Trauma with a Chopstick—Case Report— | |
JPH05310594A (ja) | 抗菌剤とこの抗菌剤を用いて物品を処理する方法 | |
Sela et al. | Effect of leukocyte hydrolases on bacteria: IX. The release of lipoteichoic acid from group A streptococci and from Strep, mutans by leukocyte extracts and by lysozyme: Relation to tissue damage in inflammatory sites | |
Majury et al. | Preliminary investigation of the mechanism of inhibition of bovine lymphocyte proliferation by Pasteurella haemolytica A1 leukotoxin | |
CA2197659A1 (en) | Antibacterial composition containing multimeric alpha-lactalbumin | |
Altemeier | Bacteriology of traumatic wounds | |
CN111150835A (zh) | 猪β-防御素2肽段在制备预防和治疗猪链球菌感染的药物组合物中的应用 | |
OAKLEY | Section of Comparative Medicine | |
Ziprin et al. | T-2 toxin effects on the serum amyloid P-component (SAP) response of Listeria monocytogenes-and Salmonella typhimurium-infected mice | |
Arslan et al. | Comparative evaluation of the effects of florfenicol and tulathromycin on clinical recovery and acute phase proteins in undifferentiated natural bovine respiratory disease | |
US20010056061A1 (en) | Synthetic, statistic thymic peptide combination and its use as a preparation with immunological and/or endocrinological effect | |
US20050227942A1 (en) | Method and agent for the prevention, inhibition and treatment of sepsis | |
Ayres | Atopic dermatitis—a new therapeutic regimen | |
Baker et al. | Protein extracts in states of hypersensitization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |